CARLSBAD, Calif. (AP) _ GenMark Diagnostics Inc. (GNMK) on Monday reported a loss of $13.3 million in its second quarter.
The Carlsbad, California-based company said it had a loss of 23 cents per share.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.
The molecular diagnostics company posted revenue of $18.4 million in the period, which topped Street forecasts. Four analysts surveyed by Zacks expected $17.9 million.
GenMark Diagnostics expects full-year revenue in the range of $85 million to $90 million.
GenMark Diagnostics shares have risen 18% since the beginning of the year. In the final minutes of trading on Monday, shares hit $5.74, a fall of 21% in the last 12 months.